menu

Keeping Pace in Immunotherapy: Management of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Clinical Considerations in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

close
0.25 credits
15 minutes
Clinical Considerations in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Squamous cell carcinoma of the head and neck is one of the most common cancers worldwide, with over 500,000 new cases and 380,000 deaths annually. In this regard, the poor outcomes associated with recurrent/metastatic squamous cell carcinoma of the head and neck represent a significant unmet medical need. For these patients, first-line pharmacologic therapy includes chemotherapy, targeted therapies, and immunotherapy, often in combination. Nonetheless, treatment selection is widely recognized as difficult due to complex patient and disease factors.

  • Disclosures of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Ana Ferreira Castro, MD
    Clinical Director
    Lenitudes Medical Center & Research
    Santa Maria da Feira, Portugal

    Consulting Fees: BMS, Merck Serono, MSD
    Speakers Bureau: BMS, Merck Serono, MSD 

    Faculty:
    Gilberto de Castro Junior, MD, PhD
    Attending Physician
    Instituto do Cancer do Estado de São Paulo
    São Paulo, Brazil

    Consulting Fees: Merck Serono, MSD
    Speakers Bureau: Merck Serono, MSD

    Zujun Li, MD
    NYU Langone Health
    New York, NY

    Dr. Li has nothing to disclose

    Ricard Mesía, MD, PhD
    Head of Medical Oncology Department
    Institut Català d'Oncologia
    Badalona, Spain

    Consulting Fees: AstraZeneca, Bayer, BMS, Merck, Monobiotics, MSD
    Speaker Bureau: BMS, Merck, MSD

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Tricia O’Leary has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe barriers to achieving the optimal management of patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN).
    • Assess and differentiate first-line treatment options for recurrent/metastatic SCCHN, including patient selection and associated adverse events.
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, radiation oncologists, pathologists, and healthcare professionals treating patients with head and neck cancer around the world, with a specific focus on Europe and China/Asia Pacific.

  • Accreditation and Credit Designation Statement

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    AGILE - Academy for Interprofessional Learning and Education - designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions.  Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes

  • Commercial Support

    This activity is supported by an independent educational grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner. 

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement”. 

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Squamous cell carcinoma of the head and neck is one of the most common cancers worldwide, with over 500,000 new cases and 380,000 deaths annually. In this regard, the poor outcomes associated with recurrent/metastatic squamous cell carcinoma of the head and neck represent a significant unmet medical need. For these patients, first-line pharmacologic therapy includes chemotherapy, targeted therapies, and immunotherapy, often in combination. Nonetheless, treatment selection is widely recognized as difficult due to complex patient and disease factors.

  • Disclosures of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Ana Ferreira Castro, MD
    Clinical Director
    Lenitudes Medical Center & Research
    Santa Maria da Feira, Portugal

    Consulting Fees: BMS, Merck Serono, MSD
    Speakers Bureau: BMS, Merck Serono, MSD 

    Faculty:
    Gilberto de Castro Junior, MD, PhD
    Attending Physician
    Instituto do Cancer do Estado de São Paulo
    São Paulo, Brazil

    Consulting Fees: Merck Serono, MSD
    Speakers Bureau: Merck Serono, MSD

    Zujun Li, MD
    NYU Langone Health
    New York, NY

    Dr. Li has nothing to disclose

    Ricard Mesía, MD, PhD
    Head of Medical Oncology Department
    Institut Català d'Oncologia
    Badalona, Spain

    Consulting Fees: AstraZeneca, Bayer, BMS, Merck, Monobiotics, MSD
    Speaker Bureau: BMS, Merck, MSD

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Tricia O’Leary has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe barriers to achieving the optimal management of patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN).
    • Assess and differentiate first-line treatment options for recurrent/metastatic SCCHN, including patient selection and associated adverse events.
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, radiation oncologists, pathologists, and healthcare professionals treating patients with head and neck cancer around the world, with a specific focus on Europe and China/Asia Pacific.

  • Accreditation and Credit Designation Statement

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    AGILE - Academy for Interprofessional Learning and Education - designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions.  Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes

  • Commercial Support

    This activity is supported by an independent educational grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner. 

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement”. 

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 11/29/20